-
Company Insights
Innovation and Patenting activity of HCL Technologies Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of HCL Technologies Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Sector Analysis
Managed Services Market Size, Trends, Drivers and Challenges, Vendor Landscape, Opportunities and Forecast to 2027
Managed Services Market Overview The global managed services market size was pegged at $789.3 billion in 2022. The market is expected to grow at a CAGR of more than 13% during the forecast period (2022-2027). The growing complexity of managing IT infrastructure within organizations creates a strong business case for enterprises to engage managed IT services. The rising cost of provisioning, operating, and managing IT infrastructure is also driving enterprises to adopt managed IT services model. Managed service providers bring...
-
Thematic Analysis
NewCloud Computing – Thematic Intelligence
Cloud Computing Thematic Report Overview The cloud services sector competes to provide the best artificial intelligence (AI) platforms and services, partly catalyzed by the emergence of generative AI. AI is now central to the cloud services market, from developing custom chips and supporting workloads and providing the models and tools necessary to develop AI-enabled solutions. The Cloud Computing  thematic intelligence report provides an overview of the cloud computing theme. It identifies the key trends impacting the growth of the theme...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceralasertib in Peritoneal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ceralasertib in Peritoneal Cancer Drug Details: Ceralasertib is under development for the treatment of head...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Drug Details: Ceralasertib is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceralasertib in Pancreatic Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ceralasertib in Pancreatic Cancer Drug Details: Ceralasertib is under development for the treatment of head...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ceralasertib in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ceralasertib in Solid Tumor Drug Details: Ceralasertib is under development for the treatment of head...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dabrafenib Mesylate in Small Intestine Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dabrafenib Mesylate in Small Intestine Cancer Drug Details: Dabrafenib (Tafinlar) is a kinase inhibitor, acts...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dabrafenib Mesylate in Nongerminomatous (Nonseminomatous) Germ Cell Tumors
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Dabrafenib Mesylate in Nongerminomatous (Nonseminomatous) Germ Cell Tumors Drug Details: Dabrafenib (Tafinlar) is a kinase...